143 related articles for article (PubMed ID: 35193807)
41. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.
Nagao T; Kinoshita T; Hojo T; Tsuda H; Tamura K; Fujiwara Y
Breast; 2012 Jun; 21(3):289-95. PubMed ID: 22277312
[TBL] [Abstract][Full Text] [Related]
42. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
Gülben K; Berberoğlu U; Kinaş V; Başkan E
Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
[TBL] [Abstract][Full Text] [Related]
43. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
[TBL] [Abstract][Full Text] [Related]
44. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer.
Jung SY; Kim HY; Nam BH; Min SY; Lee SJ; Park C; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
Breast Cancer Res Treat; 2010 Apr; 120(3):627-37. PubMed ID: 20143153
[TBL] [Abstract][Full Text] [Related]
45. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
[TBL] [Abstract][Full Text] [Related]
46. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
47. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
[TBL] [Abstract][Full Text] [Related]
48. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
Mills MN; Yang GQ; Oliver DE; Liveringhouse CL; Ahmed KA; Orman AG; Laronga C; Hoover SJ; Khakpour N; Costa RLB; Diaz R
Eur J Cancer; 2018 Jul; 98():48-58. PubMed ID: 29870876
[TBL] [Abstract][Full Text] [Related]
49. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
50. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
51. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.
Li Y; Zhang N; Zhang H; Yang Q
J Clin Pathol; 2019 Jun; 72(6):418-424. PubMed ID: 30872384
[TBL] [Abstract][Full Text] [Related]
52. Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
Haque W; Verma V; Butler EB; Teh BS
Lung Cancer; 2019 Apr; 130():93-100. PubMed ID: 30885358
[TBL] [Abstract][Full Text] [Related]
53. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
54. Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer.
Duchesneau ED; An SJ; Strassle PD; Reeder-Hayes KE; Gallagher KK; Ollila DW; Downs-Canner SM; Spanheimer PM
Ann Surg Oncol; 2022 May; 29(5):3051-3061. PubMed ID: 35039947
[TBL] [Abstract][Full Text] [Related]
55. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
Thornton MJ; Williamson HV; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Gupta AM; Hyslop T; Hwang ES; Fayanju OM
Ann Surg Oncol; 2019 Oct; 26(10):3166-3177. PubMed ID: 31342392
[TBL] [Abstract][Full Text] [Related]
57. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database.
Wang XX; Jiang YZ; Liu XY; Li JJ; Song CG; Shao ZM
Oncotarget; 2016 Apr; 7(16):22665-73. PubMed ID: 27009810
[TBL] [Abstract][Full Text] [Related]
58. [Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data].
Chen SY; Tang Y; Song YW; Wang SL; Jin J; Liu YP; Wang WH; Fang H; Ren H; Sun GY; Wang JY; Jing H; Zhang JH; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):619-625. PubMed ID: 30139034
[No Abstract] [Full Text] [Related]
59. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
60. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma.
Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M
Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
